KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions® Inc., a developer of devices to treat heart failure and related conditions, today announced that it has completed enrollment in the AMADEUS™ trial. AMADEUS™ (CArillon Mitral Annuloplasty Device European Union Study), a safety and efficacy study, is evaluating the CARILLON™ system at six centers across Europe. In June, Professor Tomasz Siminiak of the Poznan University of Medical Sciences Cardiac & Rehabilitation Hospital, implanted the final CARILLON™ devices while in Poznan, Poland. The study enrolled 30 patients and is designed to assess safety and performance at one, three, and six month endpoints.
